Forget a Cash ISA! I’d aim to make a passive income with these 2 FTSE 100 dividend stocks

I think these two FTSE 100 (INDEXFTSE:UKX) income shares appear to offer favourable prospects when compared to a Cash ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the best returns available on a Cash ISA are currently around 1.5%, buying FTSE 100 dividend shares could prove to be a shrewd move.

In many cases, it is possible to double, or even treble, your passive income when compared to Cash ISA rates.

With interest rates set to remain at their current level, or even fall, over the next few years, now could be a good time to buy these two large-cap income shares. They appear to have sound strategies that could produce capital growth alongside their income returns.

AstraZeneca

With a 3.1% dividend yield, AstraZeneca (LSE: AZN) may not be among the highest-yielding shares in the FTSE 100. However, the pharmaceutical company’s dividend growth prospects could make it a sound income opportunity for the long run.

Its recent updates have shown that its pipeline has improved dramatically in recent years after an ambitious investment programme. This could position the company for growth in a world where demographic challenges may catalyse demand for a wide range of healthcare products and services.

AstraZeneca’s defensive business model may prove to be attractive to many investors during what is a period of significant economic and political risk.

Furthermore, with its dividend expected to be covered 1.3 times by net profit in the current year, there seems to be scope for its shareholder payouts to rise at a brisk pace. This could lead to a strong and dependable passive income stream for its investors that catalyses its share price over the long run.

British Land

Real estate investment trust (REIT) British Land (LSE: BLND) is a very different investment proposition than AstraZeneca. The property company is facing a period of disruption across much of its asset base, with demand for retail units expected to come under pressure over the medium term as online shopping becomes increasingly popular.

This could cause rents to decline, which may put the company’s dividend growth rate under a degree of pressure. However, with British Land shifting its focus away from retail and towards faster-growing areas such as flexible office space, it seems to have a sound strategy that could lead to improving financial performance in the long run.

Furthermore, investors appear to have factored in the risks facing the business. It trades on a price-to-book (P/B) ratio of just 0.6, while its dividend yield of 5.4% is among the highest yields currently available in the FTSE 100.

Certainly, British Land may prove to be a relatively risky stock to own in the short run, as it aims to transition towards assets that have greater growth potential. For long-term income investors, now could be the right time to buy a slice of the business based on its high income return and wide margin of safety. It could offer high total returns in the coming years.

Peter Stephens owns shares of AstraZeneca and British Land Co. The Motley Fool UK has recommended AstraZeneca and British Land Co. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Two white male workmen working on site at an oil rig
Dividend Shares

More oil wobbles as the BP share price dives 7% in a day!

The BP share price has been wildly volatile in 2026, bouncing around with each new move in the US-Iran war.…

Read more »

British bank notes and coins
Investing Articles

Meet the 9.6%-yielding income share that could keep growing its payout!

This income share yields close to 10% -- and has grown its dividend per share year after year for well…

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

When will Barclays shares hit £10?

Barclays shares were close to £1 not so long ago, but could they do the unthinkable and make it to…

Read more »

Picture of an easyJet plane taking off.
Investing Articles

easyJet shares have bounced back before. On a P/E ratio of 6, could they do it again?

Our writer thinks easyJet shares could turn out to be a terrific bargain from a long-term perspective. So is he…

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

Could National Grid shares offer me a dividend that won’t be hurt by inflation?

National Grid aims to inflation-proof its dividend per share with a policy of annual rises that match inflation. Is our…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Here’s what happened to £1,000 invested in the past 2 stock market crashes

History may not repeat itself, but our writer reckons there are lessons to be learned from what recent stock market…

Read more »

Young Caucasian woman at the street withdrawing money at the ATM
Investing Articles

Here’s how the HSBC share price reached an all-time high… and what might be next

HSBC’s record share price reflects a strong rebound in profits and investor confidence, but future gains may be bumpier from…

Read more »

UK coloured flags waving above large crowd on a stadium sport match.
Investing Articles

Investors tempted by beaten-down Diageo shares should mark 6 May on their calendars now

Diageo is a top British blue-chip but its shares have come under fire in recent years. Harvey Jones hopes investors…

Read more »